Lung cancer is one of the most common malignancies worldwide and a major cause of cancer-related mortality. The introduction of Immunotherapy which enhance the natural skills of the immune system to fight cancerous cells by way of using monoclonal antibodies and TKI offering a high specificity in the treatment of lung cancer contrary to traditionally applied chemotherapy which lacking specificity. the novel agents are not adverse effects free treatment modality and documentation of wide spectrum of side effects from mild rash and gastrointestinal manifestations to fulminant autoimmune phenomena’s do exist.